JP2017524682A - ＣｐＧオリゴヌクレオチドを含む医薬組成物 - Google Patents

ＣｐＧオリゴヌクレオチドを含む医薬組成物 Download PDF

Info

Publication number
JP2017524682A
JP2017524682A JP2016575363A JP2016575363A JP2017524682A JP 2017524682 A JP2017524682 A JP 2017524682A JP 2016575363 A JP2016575363 A JP 2016575363A JP 2016575363 A JP2016575363 A JP 2016575363A JP 2017524682 A JP2017524682 A JP 2017524682A
Authority
JP
Japan
Prior art keywords
concentration
cpg
antigen
pharmaceutical composition
odn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524682A5 (enExample
Inventor
リゴン ワン，
リゴン ワン，
ヤン シャオ，
ヤン シャオ，
Original Assignee
チャンチュン ファープ バイオテクノロジー カンパニー リミテッド
チャンチュン ファープ バイオテクノロジー カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チャンチュン ファープ バイオテクノロジー カンパニー リミテッド, チャンチュン ファープ バイオテクノロジー カンパニー リミテッド filed Critical チャンチュン ファープ バイオテクノロジー カンパニー リミテッド
Publication of JP2017524682A publication Critical patent/JP2017524682A/ja
Publication of JP2017524682A5 publication Critical patent/JP2017524682A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016575363A 2014-06-26 2015-06-12 ＣｐＧオリゴヌクレオチドを含む医薬組成物 Pending JP2017524682A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410294142.3 2014-06-26
CN201410294142.3A CN105214083A (zh) 2014-06-26 2014-06-26 含有CpG寡核苷酸的药物组合物
PCT/CN2015/081330 WO2015196935A1 (zh) 2014-06-26 2015-06-12 含有CpG寡核苷酸的药物组合物

Publications (2)

Publication Number Publication Date
JP2017524682A true JP2017524682A (ja) 2017-08-31
JP2017524682A5 JP2017524682A5 (enExample) 2018-07-26

Family

ID=54936744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575363A Pending JP2017524682A (ja) 2014-06-26 2015-06-12 ＣｐＧオリゴヌクレオチドを含む医薬組成物

Country Status (5)

Country Link
US (1) US10052378B2 (enExample)
EP (1) EP3162379A4 (enExample)
JP (1) JP2017524682A (enExample)
CN (1) CN105214083A (enExample)
WO (1) WO2015196935A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020090445A (ja) * 2018-12-04 2020-06-11 国立大学法人大阪大学 免疫賦活剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630175A4 (en) 2017-05-31 2021-03-17 Texas Tech University System METHOD AND DEVICE FOR TREATMENT OF FOOD ALLERGIES
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
CN112007149A (zh) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 一种新型复合免疫佐剂及其应用
CN115177724A (zh) * 2019-06-28 2022-10-14 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
CN113521273A (zh) * 2020-04-17 2021-10-22 北京科兴中维生物技术有限公司 一种使用含有CpG寡聚脱氧核苷酸的复合佐剂的新冠COVID-19灭活疫苗
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
CA3202133A1 (en) * 2020-12-16 2022-06-23 Martin Gohlke Method for quantifying cpg-containing oligonucleotides in formulations comprising alum
CN115120713A (zh) * 2021-03-25 2022-09-30 四川大学 氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途
CN113304257A (zh) * 2021-04-15 2021-08-27 浙江天元生物药业有限公司 一种双佐剂新型冠状病毒灭活疫苗的制备方法及应用
CN115252772A (zh) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN117653724A (zh) 2022-09-07 2024-03-08 远大赛威信生命科学(南京)有限公司 一种用于预防乙型肝炎病毒感染的药物组合物及其应用
CN117448337B (zh) * 2023-09-15 2025-11-28 安徽智飞龙科马生物制药有限公司 CpG寡聚脱氧核苷酸、包含其的佐剂、疫苗及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521385A (ja) * 2004-11-29 2008-06-26 長春華普生物技術有限公司 アジュバントとしてのＣｐＧ含有一本鎖デオキシヌクレオチド
WO2011040535A1 (ja) * 2009-09-30 2011-04-07 東レ株式会社 Ｃ型肝炎ウイルスワクチン組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521385A (ja) * 2004-11-29 2008-06-26 長春華普生物技術有限公司 アジュバントとしてのＣｐＧ含有一本鎖デオキシヌクレオチド
WO2011040535A1 (ja) * 2009-09-30 2011-04-07 東レ株式会社 Ｃ型肝炎ウイルスワクチン組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF GENERAL VIROLOGY, vol. 87, JPN6019013451, 2006, pages 2253 - 2262, ISSN: 0004150447 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020090445A (ja) * 2018-12-04 2020-06-11 国立大学法人大阪大学 免疫賦活剤
JP7385206B2 (ja) 2018-12-04 2023-11-22 国立大学法人大阪大学 免疫賦活剤

Also Published As

Publication number Publication date
EP3162379A1 (en) 2017-05-03
CN105214083A (zh) 2016-01-06
US10052378B2 (en) 2018-08-21
EP3162379A4 (en) 2018-01-17
US20170136119A1 (en) 2017-05-18
WO2015196935A1 (zh) 2015-12-30

Similar Documents

Publication Publication Date Title
JP2017524682A (ja) ＣｐＧオリゴヌクレオチドを含む医薬組成物
JP5087758B2 (ja) アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
JP6499592B2 (ja) Ｂ型肝炎ワクチン
Wang et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice
JP6977206B2 (ja) 自然免疫を活性化する粘膜ワクチン用アジュバント
KR102254955B1 (ko) 바이러스 면역치료 약물 복합체 및 이의 용도
JP2023506440A (ja) 免疫刺激性組成物及びその用途
JP7777874B2 (ja) 免疫調節機能を有するＣｐＧ ＯＤＮ及びその使用
WO2020022272A1 (ja) インフルエンザワクチンを含む組成物
JP2024174990A (ja) Ｂ型肝炎の治療のための免疫原性組成物
CA2218701C (en) Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
JP2003520568A (ja) 高度な抗原提示プラットフォーム
CN104873969B (zh) 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗
CN108567977B (zh) 一种免疫增强剂、免疫治疗药物组合物及其制备与用途
EP1768696B1 (en) Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
TW202202623A (zh) 治療和預防冠狀病毒之成分和方法
UA128952C2 (uk) Фармацевтична композиція, яка включає поверхневі і нуклеокапсидні антигени вірусу гепатиту в
CN107693788B (zh) 一种用于预防或治疗乙型肝炎的药物组合物及其用途
CN101309931B (zh) 包含截短的hbc核心蛋白和基于皂苷的佐剂的疫苗
CN1301572A (zh) 用于疫苗的佐剂组合物
CN113058033B (zh) 一种用于预防和治疗乙型肝炎的药物组合物及其用途
WO2021154752A1 (en) Compositions and methods for treating and preventing hepatitis b and d
Tygrett et al. CpG DNA Is a Potent Enhancer of Specific
GB2440528A (en) Antigen-antibody complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190416

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191112